Key Highlights

  • Cash, cash equivalents and short-term marketable Debt securities totaled USD 498.5 million on September 30, 2026, which the company says is enough to fund operations into mid-2028.
  • The Q3 net loss came to USD 79.5 million (USD 0.93 a share), against a year-earlier USD 70.7 million (USD 1.10 a share), with the per-share figure helped by a bigger share base.
  • R&D outlays rose 13.6% to USD 68.9 million, with USD 17.0 million of that reflecting higher accrued regulatory milestone fees linked to anticipated BLA acceptance.
  • Operating cash outflow for the first nine months was USD 185.2 million, up from USD 137.2 million in 2025, at MoonLake Immunotherapeutics (NASDAQ:MLTX).

Hidradenitis Suppurativa Application Goes to the FDA

A 10-Q dated November 4, 2026 reports results for MoonLake Immunotherapeutics (NASDAQ:MLTX) through September 30, 2026. Its only program is SLK, a tri-specific nanobody that inhibits IL-17A and IL-17F, aimed at inflammatory conditions of the skin and joints. On September 30, 2026, it sent a Biologics License Application to the FDA seeking approval for moderate-to-severe hidradenitis suppurativa among patients 12 years and older. Acceptance notice is expected about 60 days after filing, with the planned review timeline pegged at roughly 74 days. In VELA, week 52 results recorded 67.2% of patients at HiSCR75 and 33.1% at HiSCR100.

Net Loss Grows as Weighted Share Count Expands

Total operating costs were USD 79.9 million, versus USD 71.4 million, split between R&D of USD 68.9 million and G&A of USD 11.0 million. Within R&D sit USD 17.0 million of accrued milestone license fees payable to MHKDG if BLA acceptance occurs, and USD 2.8 million tied to Manufacturing pre-launch stock. The net loss increased 12.5%, while the per-share loss shrank to USD 0.93 as weighted shares went from 63.4 million to 85.4 million. Over nine months, the per-share loss was USD 2.74, versus USD 2.61 previously. No product sales exist yet, and management foresees operating losses lasting at least two more years.

Psoriatic Arthritis Readouts, Upcoming Trials and Funding Exposure

The IZAR-1 psoriatic arthritis trial, reported in August 2026, hit every week 16 endpoint; 42.1% of biologic-naive patients taking 60 mg with induction reached ACR50. Comparisons against placebo remain blinded. IZAR-2 completed enrollment in September, and its initial topline data are due in the first quarter of 2027. The adolescent VELA-TEEN final topline arrives in that same window. According to the filing, comparisons across trials do not amount to head-to-head evidence. The company carries USD 100.0 million of long-term debt; the chief risks are pre-launch outlays for a commercial rollout and any FDA postponement or refusal.

Where Things Stand

Current plans stretch the cash to mid-2028, paying for regulatory review and launch work on its lone asset. Averaged over nine months, operating cash use runs about USD 62 million per quarter (calculated), and long-term debt stands at USD 100.0 million, so the runway hinges on the FDA route for MoonLake Immunotherapeutics (NASDAQ:MLTX). The filing gives no market reaction. Upcoming checkpoints include the FDA's acceptance decision, due about 60 days after September 30, the review schedule, the Phase 3 NOVA start in November and first-quarter 2027 readouts. Each marker on that list carries a date, which makes the timetable easier to monitor than the cash balance alone.